Skip to content
Clinical Trials – home

Akershus University Hospital

Verified siteinfo

Norway Sykehusveien 27, 1478 Lorenskog, Norway

  • 31 trials recruiting
  • Migraine · Multiple sclerosis · Breast cancer
  • Adults and children

About Specializations

Akershus University Hospital in Lorenskog, Norway specialises in clinical trials of conditions such as Migraine, Multiple sclerosis, Breast cancer, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

Research at Akershus University Hospital in Cardiovascular Diseases focuses on major heart and circulation conditions, especially acute myocardial infarction, atrial fibrillation, and stroke-related prevention. The trials are designed to improve emergency care, reduce the risk of recurrent events, and test whether new treatment approaches can better protect high-risk patients.

  • Evaluating a self-administered treatment approach for people with symptoms suggesting acute myocardial infarction
  • Studying stroke prevention in patients with atrial fibrillation and advanced chronic kidney disease
  • Assessing whether a treatment can improve outcomes after serious brain bleeding and related vascular emergencies

This area brings together urgent cardiovascular care and prevention research, with a strong emphasis on improving survival and reducing repeat events.

Nervous System Diseases

The Nervous System Diseases portfolio includes studies on chronic migraine and stroke-related conditions, reflecting a focus on both symptom control and better acute care. At this site, the research aims to confirm whether existing therapies can offer more reliable benefit in everyday practice and to support faster, more effective treatment decisions.

  • Testing whether atorvastatin can help prevent attacks in people with chronic migraine
  • Exploring treatment strategies for patients affected by stroke and other neurologic emergencies
  • Improving clinical outcomes through better understanding of treatment response in neurological disease

The work combines prevention research with efforts to strengthen real-world care for common and serious neurological disorders.

Neoplasms

In Neoplasms, the hospital is involved in research on advanced breast cancer in older and frailer patients. These studies aim to make cancer treatment more practical and tolerable for people who may need gentler, personalized therapy while still maintaining effectiveness.

  • Comparing treatment approaches for older breast cancer patients to find a better balance between benefit and side effects
  • Supporting more individualized cancer care for vulnerable patients with advanced breast cancer
  • Evaluating whether modified treatment strategies can improve continuation of therapy in routine oncology practice

This research reflects a patient-centered approach to oncology, with attention to treatment effectiveness, safety, and quality of life.

Digestive System Diseases

Work in Digestive System Diseases centers on primary sclerosing cholangitis, a chronic liver and bile duct disease with limited treatment options. The trials are focused on testing whether a potential therapy can improve disease markers and offer a better way to manage this challenging condition.

  • Studying a treatment for primary sclerosing cholangitis to see whether it can lower signs of inflammation and cholestasis
  • Assessing whether therapy can improve liver-related outcomes in patients with chronic biliary disease
  • Exploring options that may provide more effective symptom and disease control

The focus is on finding practical improvements for a rare but serious digestive and liver disorder.

Virus Diseases

The Virus Diseases research includes monkeypox virus disease, with studies examining how patients respond to antiviral treatment and routine care. The goal is to better understand clinical outcomes and support more informed decisions about managing emerging infectious diseases.

  • Observing outcomes in patients with mpox who receive antiviral treatment and those who do not
  • Improving knowledge of how to manage monkeypox virus disease in real-world clinical settings
  • Supporting evidence-based care for infectious disease outbreaks

This area adds an important infectious disease dimension to the site’s broader clinical research profile.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Sykehusveien 271478 LorenskogNorway
Recruiting now
31 trials
Conditions studied
69
Partner status
Verified site

More sites in LorenskogNorway

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

68 clinical trials

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Sepsis

Recruiting

Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium
  • Sponsor:Akershus University Hospital

Study Comparing Intravenous Contrast CT with Non-Contrast CT for Patients with Acute Abdominal Pain and Reduced Kidney Function Using Iohexol

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:University Of Helsinki

Study on Clopidogrel and Dalteparin Sodium for Preventing Blood Clots in Pancreatic Cancer Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Clopidogrel
  • Sponsor:Akershus University Hospital

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dabrafenib
  • Sponsor:Oslo University Hospital HF
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.